Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 6/20 | 0.53 |
| ▸ | TACR1 | P25103 | 1/20 | 0.53 |
| ▸ | CCR5 | P51681 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 4/20 | 0.51 |
| ▸ | HRH1 | P35367 | 4/20 | 0.51 |
| ▸ | DRD3 | P35462 | 4/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.51 |
| ▸ | HTR2C | P28335 | 3/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.51 |
| ▸ | HTR6 | P50406 | 3/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.51 |
| ▸ | DRD2 | P14416 | 3/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.51 |
| ▸ | HTR2B | P41595 | 3/20 | 0.51 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4234080 | 0.85 | DRD3 (0.48) | CCR2TACR1CCR5HTR2AHRH1 | |
| SCHEMBL3819961 | 0.84 | OPRL1 (0.53) | CCR2TACR1CCR5OPRM1OPRL1 | |
| SCHEMBL8246457 | 0.83 | DRD3 (0.50) | HTR2AHRH1DRD3OPRD1OPRK1 | |
| SCHEMBL13962992 | 0.79 | CCR2 (0.57) | CCR2TACR1CCR5ADRA1AADRA1D | |
| SCHEMBL4223179 | 0.79 | CACNA1B (0.53) | CCR2TACR1CCR5HTR2AHRH1 | |
| SCHEMBL6397901 | 0.76 | MCHR2 (0.53) | CCR2MCHR2 | |
| SCHEMBL7382052 | 0.76 | MCHR2 (0.58) | CCR2MCHR2 | |
| SCHEMBL3818975 | 0.76 | SIGMAR1 (0.63) | CCR2HTR2AHRH1DRD3OPRD1 | |
| SCHEMBL8693564 | 0.76 | MCHR2 (0.58) | CCR2OPRM1MCHR2 | |
| SCHEMBL4379525 | 0.75 | DRD3 (0.58) | HTR2AHRH1DRD3OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030018041-A1 | Spiroindene and spiroindane compounds | PURDUE PHARMA L.P. | 2003-01-23 | — | — | US | claimed |
| EP-1385514-B9 | SPIROINDENE AND SPIROINDANE COMPOUNDS | EURO CELTIQUE SA (LU) | 2009-08-12 | — | — | EP | disclosed |
| EP-2033644-A1 | Spiroindene and spiroindane compounds | EURO-CELTIQUE S.A. (LU) | 2009-03-11 | — | — | EP | disclosed |
| EP-1385514-B1 | SPIROINDENE AND SPIROINDANE COMPOUNDS | EURO CELTIQUE SA (LU) | 2008-11-05 | — | — | EP | disclosed |
| EP-1385514-A4 | SPIROINDENE AND SPIROINDANE COMPOUNDS | EURO CELTIQUE SA (LU) | 2005-04-13 | — | — | EP | disclosed |
| US-6828440-B2 | Analgesics; side effect reduction | EURO-CELTIQUE, S.A. (LU) | 2004-12-07 | — | — | US | disclosed |
| EP-1385514-A1 | SPIROINDENE AND SPIROINDANE COMPOUNDS | Euro-Celtique S.A. (LU) | 2004-02-04 | — | — | EP | disclosed |
| US-20030018041-A1 | Spiroindene and spiroindane compounds | PURDUE PHARMA L.P. | 2003-01-23 | — | — | US | disclosed |
| WO-2002085354-A1 | SPIROINDENE AND SPIROINDANE COMPOUNDS | EURO-CELTIQUE S.A. (LU) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018041-A1 | Spiroindene and spiroindane compounds | NR3C2, REN, NR1I2 | CCR2 334/4885TACR1 70/4885CCR5 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.